Biogen (BIIB) Stock Forecast & Price Target

Q: What analysts cover Biogen?

Biogen has been rated by research analysts at Argus , Canaccord Genuity Group , Citigroup , Evercore , Freedom Capital , Guggenheim , HC Wainwright , HSBC , JPMorgan Chase & Co. , Morgan Stanley , Oppenheimer , Piper Sandler , Rothschild & Co Redburn , Royal Bank Of Canada , Sanford C. Bernstein , The Goldman Sachs Group , Truist Financial , UBS Group , Wedbush , and Weiss Ratings in the past 90 days.

$188.83 -3.40 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$188.84 +0.01 (+0.01%)

As of 06:17 PM Eastern

Compare

Biogen - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 29 Analyst Ratings

Sell
1

Hold
13

Buy
15

Based on 29 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 1 has given a sell rating, 13 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for BIIB.

Consensus Price Target

$215.81
14.29% Upside

According to the 29 analysts' twelve-month price targets for Biogen, the average price target is $215.81. The highest price target for BIIB is $300.00, while the lowest price target for BIIB is $150.00. The average price target represents a forecasted upside of 14.29% from the current price of $188.83.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIIB Analyst Ratings Over Time

Type	Current Forecast 6/2/25 to 6/2/26	1 Month Ago 5/3/25 to 5/3/26	3 Months Ago 3/4/25 to 3/4/26	1 Year Ago 6/2/24 to 6/2/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)
Hold	13 Hold rating(s)	13 Hold rating(s)	15 Hold rating(s)	18 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$215.81	$214.23	$205.04	$191.81
Forecasted Upside	14.29% Upside	14.53% Upside	7.95% Upside	46.26% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	Broader Market
Consensus Rating Score	2.52	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	15.09% Upside	1,729.76% Upside	15.36% Upside
News Sentiment Rating	Neutral News See Recent BIIB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/27/2026	Royal Bank Of Canada 3 of 5 stars	Brian Abrahams 4 of 5 stars	Boost Target	Outperform	$222.00 ➝ $227.00	+17.57%
5/15/2026	Piper Sandler 2 of 5 stars	David Amsellem 5 of 5 stars	Reiterated Rating	Overweight	$214.00 ➝ $225.00	+17.57%
5/15/2026	Evercore 4 of 5 stars		Initiated Coverage	Outperform
5/14/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$275.00 ➝ $300.00	+55.90%
5/1/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
5/1/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$190.00 ➝ $200.00	+5.66%
5/1/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
4/30/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$200.00 ➝ $206.00	+9.85%
4/30/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$191.00 ➝ $196.00	+0.83%
Trump's gold order: the announcement they won't put on the front page (Ad) On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. Request the free guide in 30 seconds and get positioned now
4/30/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$246.00 ➝ $260.00	+33.76%
4/30/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$180.00 ➝ $190.00	+0.57%
4/30/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$201.00 ➝ $200.00	+5.87%
4/24/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$231.00 ➝ $238.00	+29.08%
4/23/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$175.00 ➝ $185.00	-2.35%
4/22/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$185.00 ➝ $225.00	+21.00%
4/13/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$193.00 ➝ $189.00	+8.94%
4/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold
4/1/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sumant Kulkarni Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$230.00 ➝ $245.00	+33.64%
3/17/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Reduce	$143.00 ➝ $150.00	-18.15%
2/19/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Equal Weight	$185.00	-3.69%
2/10/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$207.00 ➝ $236.00	+24.87%
2/9/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$231.00	+18.86%
2/9/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Phil Nadeau Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$175.00 ➝ $215.00	+6.87%
2/9/2026	Tudor Pickering Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$201.00	-0.09%
2/8/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$190.00 ➝ $200.00	-0.59%
2/6/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$165.00 ➝ $196.00	-2.82%
2/6/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$202.00 ➝ $214.00	+6.37%
11/28/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Tsai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$190.00 ➝ $210.00	+15.42%
10/31/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$255.00 ➝ $250.00	+67.10%
9/24/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
9/24/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ami Fadia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
2/13/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Outperform	$244.00 ➝ $224.00	+61.69%
2/11/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$178.00 ➝ $163.00	+16.94%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$292.00 ➝ $292.00	+46.34%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:32 PM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 1, 2026. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

Biogen Inc. recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share significantly higher than the consensus estimate, indicating robust financial performance.
The current stock price is around $191, which may present a buying opportunity for investors looking to enter at a favorable valuation.
Analysts have generally raised their price targets following positive earnings reports, suggesting a potential for stock appreciation in the near term.
Biogen Inc. has a diverse portfolio focused on neurological and neurodegenerative diseases, which positions the company well in a growing market with significant unmet medical needs.
Recent analyst ratings show a mix of buy and hold recommendations, indicating confidence in the company's future performance among investment professionals.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

Recent disclosures regarding the Apellis transaction indicate a projected earnings headwind, which could negatively impact short-term profitability and investor sentiment.
Some analysts have slightly reduced their price targets, which may signal caution and potential profit-taking among investors.
Despite recent earnings beats, there are concerns about constrained near-term growth, as indicated by mixed analyst reactions and lowered EPS expectations for future years.
The stock has experienced a decline of about 6.4% recently, which may raise concerns about its short-term performance and market volatility.
With a significant number of hold ratings, there may be a lack of strong bullish sentiment, suggesting that investors should proceed with caution.

BIIB Forecast - Frequently Asked Questions

According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $215.81, with a high forecast of $300.00 and a low forecast of $150.00.

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There is currently 1 sell rating, 13 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.

According to analysts, Biogen's stock has a predicted upside of 14.29% based on their 12-month stock forecasts.

Over the previous 90 days, Biogen's stock had 5 upgrades by analysts.

Biogen has been rated by research analysts at Argus, Canaccord Genuity Group, Citigroup, Evercore, Freedom Capital, Guggenheim, HC Wainwright, HSBC, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, The Goldman Sachs Group, Truist Financial, UBS Group, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Biogen more than other "medical" companies. The consensus rating for Biogen is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Biogen Recommendations

This page (NASDAQ:BIIB) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target